Dr. Falchook is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Williams St
300
Denver, CO 80218Phone+1 720-754-2610Fax+1 720-754-2659
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- Baylor College of MedicineResidency, Internal Medicine, 2001 - 2004
- Louisiana State University School of Medicine in New OrleansClass of 2001
Certifications & Licensure
- CO State Medical License 2004 - 2025
- TX State Medical License 2004 - 2015
- PA State Medical License 2004 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Bevacizumab and Bortezomib in Patients With Advanced Malignancy Start of enrollment: 2007 Jan 01
- Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients Start of enrollment: 2005 Jan 01
- Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer Start of enrollment: 2007 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 75 citationsBRAF Mutations in Advanced Cancers: Clinical Characteristics and OutcomesHazem E El-Osta, Gerald S. Falchook, Apostolia Maria Tsimberidou, David S. Hong, Aung Naing
Plos One. 2011-10-19 - 27 citationsA phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.Manish R. Patel, Gerald Steven Falchook, Kensuke Hamada, Lukas Makris, Johanna C. Bendell
Cancer Medicine. 2021-02-05 - 1253 citationsThe clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke
Nature. 2019-10-30
Journal Articles
- KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
- Plain Language Summary of the Development of Tepotinib: A Treatment for a Subtype of Non-Small Cell Lung Cancer Called MET Exon 14 SkippingMarch 31st, 2023
- Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
- Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual MeetingMay 28th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: